GLPwatch

Closed Loop System With Pramlintide Versus Exenatide

NCT01269008 · Completed

Last updated 2026-05-28

This study tested whether a closed-loop insulin delivery system combined with pramlintide works better than one combined with exenatide to control blood sugar levels in people with type 1 diabetes.

Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Non-randomized, open-label (no blinding) treatment study
Participants 13 people
Who can join Ages 18–30 · all sexes
Timeline Started 2010-12 · est. completion 2013-01
Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01269008 ↗

Description as written by the study sponsor.

Post-prandial hyperglycemia occurs despite meticulous carbohydrate counting and rapid acting insulin therapy. Furthermore, this occurs even in the setting of the closed loop system. Currently the algorithm used for calculating the glucose-responsive insulin delivery cannot respond in a timely fashion to the glucose absorption resulting from a meal. In diabetes, there is paradoxical immediate post-prandial hyperglucagonemia that results in immediate post-prandial hyperglycemia. Amylin deficiency and/or dysregulated GLP-1 seems to be the etiology. Pharmacologic replacement of these hormones alleviates immediate post-prandial hyperglycemia in diabetes. With this protocol, the investigators would like to optimize treatment of T1DM by physiologic replacement of hormones in addition to insulin and in the process also optimize the insulin algorithm. This is a paired, randomized, and controlled comparison of pramlintide and insulin versus exenatide and insulin Vs insulin monotherapy using the ePID closed-loop system for insulin delivery. The investigators will stratify the study subjects into the following sub-groups of 5 subjects of 22-30 years old, 4 subjects of 18-21 years old, 4 subjects of 16-18 years old. The investigators would also begin the study with the 21-25 year patient sub-group and then transition to the other sub-groups after evaluating all the safety issues. 22-30 year old ones would be considered as an adult subset, 18-21 year olds would be considered pediatric subset according to the guidelines of FDA's Center for Devices and Radiological Health (CDRH) and 16-18 year olds are considered typical pediatric population. At this time, Spanish-speaking subjects will not be recruited because Medtronic Minimed as yet does not have any literature in Spanish that may used in explaining the study to this group of patients. When in the future Medtronic is able to provide us with the appropriate Spanish literature, the investigators will at that time amend the protocol to include this group of subjects.

Treatments tested

Main thing measuredBetter meal and post meal sugars on the closed loop device using the study medications.
SponsorAlbert Einstein College of Medicine
Conditions studiedType 1 Diabetes
GLP-1 drugs exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01269008 ↗